Compare LAND & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAND | XFOR |
|---|---|---|
| Founded | 1997 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 360.0M | 324.4M |
| IPO Year | 2013 | N/A |
| Metric | LAND | XFOR |
|---|---|---|
| Price | $9.14 | $3.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $28.50 |
| AVG Volume (30 Days) | 518.9K | ★ 879.6K |
| Earning Date | 02-18-2026 | 11-05-2025 |
| Dividend Yield | ★ 6.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $67,936,000.00 | $33,979,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 2925.74 |
| 52 Week Low | $8.47 | $1.35 |
| 52 Week High | $11.93 | $26.83 |
| Indicator | LAND | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 56.98 | 50.13 |
| Support Level | $8.78 | $3.50 |
| Resistance Level | $8.90 | $4.56 |
| Average True Range (ATR) | 0.18 | 0.30 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 96.55 | 38.14 |
Gladstone Land Corp is an externally-managed, agricultural REIT. It is mainly in the business of owning and leasing farmland. It manages operations in one reporting segment. It is focused on the ownership of high-quality farms and farm-related properties that are leased on a triple-net basis to tenants with a good operating history and deep farming resources. The farmland is predominantly concentrated in locations where farmers are able to grow either fresh produce annual row crops (e.g., certain berries and vegetables), which are typically planted and harvested annually, or certain permanent crops (e.g., almonds, blueberries, pistachios, and wine grapes). To a much lesser extent, it also own farms that grow certain commodity crops (e.g., corn and beans).
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.